{"organizations": [], "uuid": "899d3de3f4af7dbd2dfd8452a453f8e9e85a1569", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-rxi-pharmaceuticals-says-49-mln-re/brief-rxi-pharmaceuticals-says-4-9-mln-registered-direct-offering-priced-at-the-market-idUSASC09VB0", "country": "US", "domain_rank": 408, "title": "BRIEF-Rxi Pharmaceuticals Says $4.9 Mln Registered Direct Offering Priced At-The Market", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-09T21:09:00.000+03:00", "replies_count": 0, "uuid": "899d3de3f4af7dbd2dfd8452a453f8e9e85a1569"}, "author": "", "url": "https://www.reuters.com/article/brief-rxi-pharmaceuticals-says-49-mln-re/brief-rxi-pharmaceuticals-says-4-9-mln-registered-direct-offering-priced-at-the-market-idUSASC09VB0", "ord_in_thread": 0, "title": "BRIEF-Rxi Pharmaceuticals Says $4.9 Mln Registered Direct Offering Priced At-The Market", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "rxi pharmaceuticals corp", "sentiment": "none"}, {"name": "rxi pharmaceuticals", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 9, 2018 / 6:10 PM / in 8 minutes BRIEF-Rxi Pharmaceuticals Says $4.9 Mln Registered Direct Offering Priced At-The Market Reuters Staff \nApril 9 (Reuters) - Rxi Pharmaceuticals Corp: \n* RXI PHARMACEUTICALS ANNOUNCES $4.9 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET \n* ENTERED AGREEMENTS FOR PURCHASE OF 1.5 MLN SHARES AT $3.24375/SHARE IN REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET \n* TO USE PROCEEDS FROM OFFERING TO FUND PRECLINICAL & CLINICAL DEVELOPMENT, OTHER RESEARCH & DEVELOPMENT ACTIVITIES, AMONG OTHERS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-09T21:09:00.000+03:00", "crawled": "2018-04-09T21:26:00.008+03:00", "highlightTitle": ""}